^
Association details:
Biomarker:LMNA-NTRK1 fusion
Cancer:Breast Cancer
Drug:Zykadia (ceritinib) (ALK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

Published date:
05/15/2020
Excerpt:
Similarly, expression of the EML4-ALK fusion also activated growth factor signaling pathways and caused resistance to estrogen depletion and induced sensitivity to the ALK inhibitor, Ceritinib
DOI:
10.1158/1538-7445.AM2020-5280